Oncomed Pharmaceuticals Inc (OMED) 26.06 $OMED
OncoMed Starts Dosing in Non-Small Cell Lung Cancer Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 3:20PM CST
OncoMed Pharmaceuticals (OMED) initiated patient dosing in a phase II study (DENALI) on its experimental cancer treatment, demcizumab, being evaluated for the treatment of patients with first-line advanced-stage non-small cell lung cancer.
OMED: 26.06 (+0.30), LLY: 70.56 (+0.03), PRTA: 22.89 (+0.13), CELG: 115.88 (+0.16)
Commit To Buy OncoMed Pharmaceuticals At $20, Earn 23.9% Annualized Using Options
at The Street - Thu Feb 05, 11:13AM CST
Investors eyeing a purchase of OncoMed Pharmaceuticals Inc. shares, but cautious about paying the going market price of $22.72/share, might benefit from considering selling puts among the alternative strategies at their disposal.
OMED: 26.06 (+0.30)
OncoMed Initiates Dosing in Phase 2 Clinical Trial of Demcizumab for the Treatment of Non-Small Cell Lung Cancer
GlobeNewswire - Wed Feb 04, 7:30AM CST
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, announced that patient dosing has begun in the double-blinded, placebo-controlled, randomized Phase 2 clinical trial of demcizumab (anti-DLL4, OMP-21M18) for the treatment of patients with first-line advanced-stage non-small cell lung cancer (NSCLC).
OMED: 26.06 (+0.30)
Did Researchers Just Discover the Cause of Pancreatic Cancer?
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 31, 11:23AM CST
Source: Flickr user Sunil Joshi. Although no cancer diagnosis is welcome, perhaps no cancer type comes with a more frightening outlook than pancreatic cancer. According to data from the American Cancer Society, pancreatic cancer is the twelfth...
VSTM: 7.93 (-0.44), OMED: 26.06 (+0.30), PFE: 34.64 (-0.23), NLNK: 38.84 (+1.51), THLD: 4.03 (+0.21), CELG: 115.88 (+0.16)
3 Biotech Stocks You Won't Want To Miss In 2015
BPD Research - at Seeking Alpha - Fri Jan 30, 10:30AM CST
VSTM: 7.93 (-0.44), OMED: 26.06 (+0.30), STML: 14.07 (-0.10)
OncoMed stem cell antibody tagged an Orphan Drug
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 10:18AM CST
OMED: 26.06 (+0.30)
FDA Grants Orphan Drug Designations to OncoMed's Tarextumab for the Treatment of Pancreatic and Small Cell Lung Cancer
GlobeNewswire - Thu Jan 29, 9:04AM CST
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that the U.S. Food and Drug Administration's Office of Orphan Products Development (OOPD) has granted orphan drug designation to tarextumab (anti-Notch 2/3, OMP-59R5) for the treatment of both pancreatic cancer and small cell lung cancer.
OMED: 26.06 (+0.30)
Recent Offering Provides Great Opportunity To Buy Verastem Before Significant 2015 Catalysts
BPD Research - at Seeking Alpha - Wed Jan 28, 6:25PM CST
VSTM: 7.93 (-0.44), OMED: 26.06 (+0.30)
OncoMed Pharmaceuticals to Present at the BIO CEO and Investor and Leerink Global Healthcare Conferences in February
GlobeNewswire - Wed Jan 28, 7:30AM CST
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced its participation at two investor conferences during the month of February.
OMED: 26.06 (+0.30)
OncoMed Presents Final Phase 1b Safety, Efficacy and Biomarker Data for Tarextumab in Pancreatic Cancer at the 2015 Gastrointestinal Cancer Symposium
GlobeNewswire - Fri Jan 16, 1:30PM CST
Median Overall Survival of 14.6 Months in Tumor Notch3 High Patients and 11.6 Months in All Patients
OMED: 26.06 (+0.30)
OncoMed Starts Expansion Stage Study for Solid Tumor Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 16, 12:50PM CST
OncoMed Pharmaceuticals, Inc. (OMED) has enrolled the first biomarker-selected patient in the expansion stage of a phase I study on OMP-52M51.
OMED: 26.06 (+0.30), AUXL: 36.47 (-0.06), ALXN: 182.29 (+6.02), GSK: 47.94 (+1.99)
OncoMed Enrolls First Biomarker-Selected Patient in Expansion Stage of Anti-Notch1 Phase 1a Trial in Solid Tumors
GlobeNewswire - Thu Jan 15, 7:59AM CST
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced the enrollment of the first biomarker-selected patient in its anti-Notch1 antibody (OMP-52M51) Phase 1a solid tumor clinical trial. The advancement to the predictive biomarker expansion stage triggered a $5 million milestone from OncoMed's partner, GlaxoSmithKline (GSK).
OMED: 26.06 (+0.30), GSK: 47.94 (+1.99)
OncoMed to Present Clinical Data and Biomarker Analysis for Tarextumab at the 2015 Gastrointestinal Cancer Symposium
GlobeNewswire - Tue Jan 13, 7:56AM CST
OncoMed Pharmaceuticals Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, will present new Phase Ib data for the company's tarextumab (anti-Notch 2/3, OMP-59R5) program at the upcoming 2015 Gastrointestinal Cancer Symposium being held January 15-17 in San Francisco, CA. OncoMed is currently conducting two separate randomized Phase 2 clinical trials of tarextumab: the ALPINE trial in first-line metastatic pancreatic cancer and the PINNACLE study in first-line extensive-stage small cell lung cancer.
OMED: 26.06 (+0.30)
OncoMed Pre-Announces 2014 Year-End Cash Balance and Provides 2015 Guidance
GlobeNewswire - Mon Jan 12, 8:16AM CST
Begins 2015 with $232 Million in Cash
OMED: 26.06 (+0.30)
Jim Cramer's 'Mad Money' Recap: You'll Make More Money Buying Into Panic
at The Street - Thu Jan 08, 7:23PM CST
Cramer says the markets suffered from a 'depressive mood disorder' but those investors who obeyed their rational brains made a ton of mad money.
CXO: 117.11 (+1.51), CYTK: 7.78 (+1.29), MNST: 117.74 (-1.77), LMT: 196.95 (-0.53), ACT: 285.37 (+3.71), EA: 56.39 (+0.20), OMED: 26.06 (+0.30), UTX: 121.25 (+1.66), DAL: 44.50 (-0.31), GMCR: 118.53 (+0.56), SKX: 66.09 (-0.06), ED: 63.92 (-1.69), JBLU: 16.83 (+0.09), INTC: 34.36 (+0.23), LUV: 43.30 (-0.20), AGN: 229.49 (+1.87), RCL: 75.56 (-1.19), SAVE: 79.32 (-0.80), AAL: 48.39 (+0.51), AAPL: 127.08 (+0.62), KING: 16.70 (+1.96), MNK: 115.01 (+2.51), CY: 14.76 (+0.01), ANW: 14.92 (+0.25), SE: 36.81 (+0.61), KR: 72.86 (+0.41), SWKS: 81.85 (-0.57), HES: 76.83 (+2.12), BLOX: 20.49 (+0.82), EW: 134.23 (+1.89), DIS: 104.17 (+0.59), SN: 15.21 (-0.12), BAC: 16.61 (-0.06), BMY: 60.04 (+0.56), UA: 73.76 (-0.19), TTWO: 28.40 (+0.96), PM: 82.87 (-0.82), CG: 28.18 (+0.04), ISIS: 63.86 (-0.43), CVX: 112.78 (+1.92), AVGO: 110.15 (+0.45), JCI: 48.50 (+0.50)
OncoMed Pharmaceuticals (OMED) Stock: Weak On High Volume Today
at The Street - Thu Jan 08, 9:16AM CST
Trade-Ideas LLC identified OncoMed Pharmaceuticals (OMED) as a weak on high relative volume candidate
OMED: 26.06 (+0.30)
OncoMed Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Wed Jan 07, 7:30AM CST
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that Paul J. Hastings, Chairman and Chief Executive Officer, will present at the 33 Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15, 2015 at 7:30 am Pacific Time.
JPM: 59.67 (+0.10), OMED: 26.06 (+0.30)
OncoMed Doses First Patient in Phase 1 Clinical Trial of Novel Anti-DLL4/VEGF Bispecific Antibody
GlobeNewswire - Mon Jan 05, 7:30AM CST
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced dosing of the first patient in its anti-DLL4/VEGF bispecific antibody (OMP-305B83) Phase 1a clinical trial. The anti-DLL4/VEGF bispecific antibody is designed to have both anti-cancer stem cell and anti-angiogenic activity.
OMED: 26.06 (+0.30), CELGZ: 3.17 (-0.04)
OncoMed Pharmaceuticals (OMED) Crumbles: Stock Falls by 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 7:54AM CST
OncoMed Pharmaceuticals has been witnessing a flat trend in its current year loss estimate and its share price has been falling for past few weeks
OMED: 26.06 (+0.30), AFFX: 11.45 (+0.02)
3 Large Cap Biotech Stocks That Could Pay Dividends, But Won't
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 07, 11:39AM CST
Source: Flickr user Tax Credits Dividend paying companies are a key part of any investor's long-haul portfolio, but investors that lean toward high growth industries like biotechnology have few dividend-paying options. Despite multibillion...
BIIB: 391.66 (-0.45), ISIS: 63.86 (-0.43), OMED: 26.06 (+0.30), GILD: 101.90 (+1.10), TEVA: 56.77 (-0.58), EPZM: 21.58 (+0.08), AGIO: 118.55 (+0.11), SNY: 49.42 (+0.82), FOLD: 8.36 (-0.11), XLRN: 38.02 (+0.07), NVS: 102.20 (-0.17), CELG: 115.88 (+0.16)
OncoMed Starts Dosing in Non-Small Cell Lung Cancer Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 3:20PM CST
OncoMed Pharmaceuticals (OMED) initiated patient dosing in a phase II study (DENALI) on its experimental cancer treatment, demcizumab, being evaluated for the treatment of patients with first-line advanced-stage non-small cell lung cancer.
OMED: 26.06 (+0.30), LLY: 70.56 (+0.03), PRTA: 22.89 (+0.13), CELG: 115.88 (+0.16)
Commit To Buy OncoMed Pharmaceuticals At $20, Earn 23.9% Annualized Using Options
at The Street - Thu Feb 05, 11:13AM CST
Investors eyeing a purchase of OncoMed Pharmaceuticals Inc. shares, but cautious about paying the going market price of $22.72/share, might benefit from considering selling puts among the alternative strategies at their disposal.
OMED: 26.06 (+0.30)
OncoMed Initiates Dosing in Phase 2 Clinical Trial of Demcizumab for the Treatment of Non-Small Cell Lung Cancer
GlobeNewswire - Wed Feb 04, 7:30AM CST
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, announced that patient dosing has begun in the double-blinded, placebo-controlled, randomized Phase 2 clinical trial of demcizumab (anti-DLL4, OMP-21M18) for the treatment of patients with first-line advanced-stage non-small cell lung cancer (NSCLC).
OMED: 26.06 (+0.30)
Did Researchers Just Discover the Cause of Pancreatic Cancer?
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 31, 11:23AM CST
Source: Flickr user Sunil Joshi. Although no cancer diagnosis is welcome, perhaps no cancer type comes with a more frightening outlook than pancreatic cancer. According to data from the American Cancer Society, pancreatic cancer is the twelfth...
VSTM: 7.93 (-0.44), OMED: 26.06 (+0.30), PFE: 34.64 (-0.23), NLNK: 38.84 (+1.51), THLD: 4.03 (+0.21), CELG: 115.88 (+0.16)
3 Biotech Stocks You Won't Want To Miss In 2015
BPD Research - at Seeking Alpha - Fri Jan 30, 10:30AM CST
VSTM: 7.93 (-0.44), OMED: 26.06 (+0.30), STML: 14.07 (-0.10)
OncoMed stem cell antibody tagged an Orphan Drug
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 10:18AM CST
OMED: 26.06 (+0.30)
FDA Grants Orphan Drug Designations to OncoMed's Tarextumab for the Treatment of Pancreatic and Small Cell Lung Cancer
GlobeNewswire - Thu Jan 29, 9:04AM CST
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that the U.S. Food and Drug Administration's Office of Orphan Products Development (OOPD) has granted orphan drug designation to tarextumab (anti-Notch 2/3, OMP-59R5) for the treatment of both pancreatic cancer and small cell lung cancer.
OMED: 26.06 (+0.30)
Recent Offering Provides Great Opportunity To Buy Verastem Before Significant 2015 Catalysts
BPD Research - at Seeking Alpha - Wed Jan 28, 6:25PM CST
VSTM: 7.93 (-0.44), OMED: 26.06 (+0.30)
OncoMed Pharmaceuticals to Present at the BIO CEO and Investor and Leerink Global Healthcare Conferences in February
GlobeNewswire - Wed Jan 28, 7:30AM CST
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced its participation at two investor conferences during the month of February.
OMED: 26.06 (+0.30)
OncoMed Presents Final Phase 1b Safety, Efficacy and Biomarker Data for Tarextumab in Pancreatic Cancer at the 2015 Gastrointestinal Cancer Symposium
GlobeNewswire - Fri Jan 16, 1:30PM CST
Median Overall Survival of 14.6 Months in Tumor Notch3 High Patients and 11.6 Months in All Patients
OMED: 26.06 (+0.30)
OncoMed Starts Expansion Stage Study for Solid Tumor Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 16, 12:50PM CST
OncoMed Pharmaceuticals, Inc. (OMED) has enrolled the first biomarker-selected patient in the expansion stage of a phase I study on OMP-52M51.
OMED: 26.06 (+0.30), AUXL: 36.47 (-0.06), ALXN: 182.29 (+6.02), GSK: 47.94 (+1.99)
OncoMed Enrolls First Biomarker-Selected Patient in Expansion Stage of Anti-Notch1 Phase 1a Trial in Solid Tumors
GlobeNewswire - Thu Jan 15, 7:59AM CST
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced the enrollment of the first biomarker-selected patient in its anti-Notch1 antibody (OMP-52M51) Phase 1a solid tumor clinical trial. The advancement to the predictive biomarker expansion stage triggered a $5 million milestone from OncoMed's partner, GlaxoSmithKline (GSK).
OMED: 26.06 (+0.30), GSK: 47.94 (+1.99)
OncoMed to Present Clinical Data and Biomarker Analysis for Tarextumab at the 2015 Gastrointestinal Cancer Symposium
GlobeNewswire - Tue Jan 13, 7:56AM CST
OncoMed Pharmaceuticals Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, will present new Phase Ib data for the company's tarextumab (anti-Notch 2/3, OMP-59R5) program at the upcoming 2015 Gastrointestinal Cancer Symposium being held January 15-17 in San Francisco, CA. OncoMed is currently conducting two separate randomized Phase 2 clinical trials of tarextumab: the ALPINE trial in first-line metastatic pancreatic cancer and the PINNACLE study in first-line extensive-stage small cell lung cancer.
OMED: 26.06 (+0.30)
OncoMed Pre-Announces 2014 Year-End Cash Balance and Provides 2015 Guidance
GlobeNewswire - Mon Jan 12, 8:16AM CST
Begins 2015 with $232 Million in Cash
OMED: 26.06 (+0.30)
Jim Cramer's 'Mad Money' Recap: You'll Make More Money Buying Into Panic
at The Street - Thu Jan 08, 7:23PM CST
Cramer says the markets suffered from a 'depressive mood disorder' but those investors who obeyed their rational brains made a ton of mad money.
CXO: 117.11 (+1.51), CYTK: 7.78 (+1.29), MNST: 117.74 (-1.77), LMT: 196.95 (-0.53), ACT: 285.37 (+3.71), EA: 56.39 (+0.20), OMED: 26.06 (+0.30), UTX: 121.25 (+1.66), DAL: 44.50 (-0.31), GMCR: 118.53 (+0.56), SKX: 66.09 (-0.06), ED: 63.92 (-1.69), JBLU: 16.83 (+0.09), INTC: 34.36 (+0.23), LUV: 43.30 (-0.20), AGN: 229.49 (+1.87), RCL: 75.56 (-1.19), SAVE: 79.32 (-0.80), AAL: 48.39 (+0.51), AAPL: 127.08 (+0.62), KING: 16.70 (+1.96), MNK: 115.01 (+2.51), CY: 14.76 (+0.01), ANW: 14.92 (+0.25), SE: 36.81 (+0.61), KR: 72.86 (+0.41), SWKS: 81.85 (-0.57), HES: 76.83 (+2.12), BLOX: 20.49 (+0.82), EW: 134.23 (+1.89), DIS: 104.17 (+0.59), SN: 15.21 (-0.12), BAC: 16.61 (-0.06), BMY: 60.04 (+0.56), UA: 73.76 (-0.19), TTWO: 28.40 (+0.96), PM: 82.87 (-0.82), CG: 28.18 (+0.04), ISIS: 63.86 (-0.43), CVX: 112.78 (+1.92), AVGO: 110.15 (+0.45), JCI: 48.50 (+0.50)
OncoMed Pharmaceuticals (OMED) Stock: Weak On High Volume Today
at The Street - Thu Jan 08, 9:16AM CST
Trade-Ideas LLC identified OncoMed Pharmaceuticals (OMED) as a weak on high relative volume candidate
OMED: 26.06 (+0.30)
OncoMed Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Wed Jan 07, 7:30AM CST
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that Paul J. Hastings, Chairman and Chief Executive Officer, will present at the 33 Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15, 2015 at 7:30 am Pacific Time.
JPM: 59.67 (+0.10), OMED: 26.06 (+0.30)
OncoMed Doses First Patient in Phase 1 Clinical Trial of Novel Anti-DLL4/VEGF Bispecific Antibody
GlobeNewswire - Mon Jan 05, 7:30AM CST
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced dosing of the first patient in its anti-DLL4/VEGF bispecific antibody (OMP-305B83) Phase 1a clinical trial. The anti-DLL4/VEGF bispecific antibody is designed to have both anti-cancer stem cell and anti-angiogenic activity.
OMED: 26.06 (+0.30), CELGZ: 3.17 (-0.04)
OncoMed Pharmaceuticals (OMED) Crumbles: Stock Falls by 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 7:54AM CST
OncoMed Pharmaceuticals has been witnessing a flat trend in its current year loss estimate and its share price has been falling for past few weeks
OMED: 26.06 (+0.30), AFFX: 11.45 (+0.02)
3 Large Cap Biotech Stocks That Could Pay Dividends, But Won't
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 07, 11:39AM CST
Source: Flickr user Tax Credits Dividend paying companies are a key part of any investor's long-haul portfolio, but investors that lean toward high growth industries like biotechnology have few dividend-paying options. Despite multibillion...
BIIB: 391.66 (-0.45), ISIS: 63.86 (-0.43), OMED: 26.06 (+0.30), GILD: 101.90 (+1.10), TEVA: 56.77 (-0.58), EPZM: 21.58 (+0.08), AGIO: 118.55 (+0.11), SNY: 49.42 (+0.82), FOLD: 8.36 (-0.11), XLRN: 38.02 (+0.07), NVS: 102.20 (-0.17), CELG: 115.88 (+0.16)
